A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), Resistance Training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients - ACCeRT Study

<p>Abstract</p> <p>Background</p> <p>Cancer cachexia is a syndrome of progressive weight loss. Non-small cell lung cancer patients experience a high incidence of cachexia of 61%. Research into methods to combat cancer cachexia in various tumour sites has recently progre...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Rogers Elaine S, MacLeod Roderick D, Stewart Joanna, Bird Stephen P, Keogh Justin WL
Format: Artigo
Jezik:Inglês
Izdano: BMC 2011-11-01
Serija:BMC Cancer
Online dostop:http://www.biomedcentral.com/1471-2407/11/493
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki